Who
Octavio Espinoza
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Ligand Pharmaceuticals.
In numbers
- Trades disclosed
- 161
- Buys
- 1
- Sells
- 12
- Bought
- $156K
- Sold
- $28.0M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 9 Nov 2022
- Last trade
- 12 Aug 2026
- Last filed
- 14 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 12 Aug 2026filed 14 Aug 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $855K16,179 at $52.84 | filing |
| 12 Aug 2026filed 14 Aug 2026 | LGND Ligand Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,348 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | LGND Ligand Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,074 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $145K2,074 at $70.04 | filing |
| 12 Aug 2026filed 14 Aug 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $160K2,869 at $55.75 | filing |
| 12 Aug 2026filed 14 Aug 2026 | LGND Ligand Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,869 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | LGND Ligand Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —7,171 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | LGND Ligand Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —16,179 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | LGND Ligand Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,348 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | LGND Ligand Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,074 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $410K7,171 at $57.22 | filing |
| 12 Aug 2026filed 14 Aug 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $230K3,348 at $68.74 | filing |
| 12 Aug 2026filed 14 Aug 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $9.2M31,641 at $292.07 | filing |
| 12 Aug 2026filed 14 Aug 2026 | LGND Ligand Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,869 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | LGND Ligand Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —7,171 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | LGND Ligand Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —16,179 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $855K16,179 at $52.84 | filing |
| 12 Aug 2026filed 14 Aug 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $145K2,074 at $70.04 | filing |
| 12 Aug 2026filed 14 Aug 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $160K2,869 at $55.75 | filing |
| 12 Aug 2026filed 14 Aug 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $410K7,171 at $57.22 | filing |
News
Analyzing Inhibrx Biosciences (NASDAQ:INBX) and Ligand Pharmaceuticals (NASDAQ:LGND)LGND · tickerreport.com · 23 Oct 2026
0 headlines in the last 90 days name Octavio Espinoza; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.